Assessment of nerve growth factor levels and clinical indicators for outcome prediction in first-episode schizophrenia

Figure 1 Dynamic changes, intergroup differences, and stratified analysis of treatment response of serum nerve growth factor levels in first-episode psychosis patients. A: Nerve growth factor (NGF) over the five assessment time points (W0: Before antipsychotic treatment; W2: After 2 weeks; W4: After 4 weeks; W6: After 6 weeks; W8: After 8 weeks); B: Comparison of serum NGF levels between the first-episode psychosis and healthy control groups; C: Changes in baseline NGF levels after 8 weeks of medication treatment in the response group (n = 50) and the non-response group (n = 28). NGF: Nerve growth factor; FEP: First-episode psychosis patients who had never received medication; HC: Healthy controls.